Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Depreciation and Depletion (2023 - 2025)

Historic Depreciation and Depletion for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to $39000.0.

  • Mereo BioPharma's Depreciation and Depletion fell 6100.0% to $39000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $159000.0, marking a year-over-year decrease of 4903.85%. This contributed to the annual value of $143000.0 for FY2024, which is 2850.0% down from last year.
  • Per Mereo BioPharma's latest filing, its Depreciation and Depletion stood at $39000.0 for Q3 2025, which was down 6100.0% from $44000.0 recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma's Depreciation and Depletion peaked at $100000.0 during Q2 2023, and registered a low of $38000.0 during Q4 2024.
  • Over the past 3 years, Mereo BioPharma's median Depreciation and Depletion value was $44000.0 (recorded in 2025), while the average stood at $64818.2.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first changed by 0.0% in 2024, then plummeted by 6100.0% in 2025.
  • Over the past 3 years, Mereo BioPharma's Depreciation and Depletion (Quarter) stood at $71000.0 in 2023, then plummeted by 46.48% to $38000.0 in 2024, then grew by 2.63% to $39000.0 in 2025.
  • Its Depreciation and Depletion stands at $39000.0 for Q3 2025, versus $44000.0 for Q2 2025 and $38000.0 for Q1 2025.